The session is slated for 9:10 a.m. ET and will be broadcast live through the company’s investor relations portal. For those unable to attend the real-time stream, an archived version of the discussion will remain accessible for a period of 30 days following the event.

ADC Therapeutics continues to center its operations on ZYNLONTA, a CD19-directed antibody drug conjugate currently approved for treating relapsed or refractory diffuse large B-cell lymphoma. As the company navigates clinical trials and regulatory pathways for expanded applications, the conference appearance serves as a key touchpoint for stakeholders monitoring the firm's commercial progress and its clinical pipeline, which includes combination therapies and earlier-line treatment options.